Simultaneous Sessions

BORTEZOMIB (VELCADE)-MELPHALAN-PREDNISONE (VMP) VERSUS VELCADE-THALIDOMIDE-PREDNISONE (VTP) IN ELDERLY UNTREATED MULTIPLE MYELOMA (MM) PATIENTS
M.V. Mateos, A. Oriol, J. Martínez, M.T. Cibeira, R. de Paz, M.J. Terol, J. García- Laraña, E. Bengoechea, R. Martínez, A. Martín, F. de Arriba, L. Palomera, J.M. Hernández, J.L. Bello, M.L. Martín, Y. González, J.J. Lahuerta, J. Bladé, J. San Miguel (University Hospital of Salamanca, Salamanca, Spain)

BORTEZOMIB, MELPHALAN, PREDNISONE AND THALIDOMIDE (VMPT) VERSUS BORTEZOMIB, MELPHALAN AND PREDNISONE (VMP) IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS: A PROSPECTIVE, RANDOMIZED, PHASE III STUDY
A. Palumbo, S. Bringhen, D. Rossi, R. Ria, S. Berretta, M. Offidani, F. Patriarca, C. Nozzoli, A. Levi, T. Guglielmelli, G. Benevolo, V. Callea, A.M. Liberati, C. Crippa, N. Di Renzo, L. Catalano, G. De Sabbata, R. Rizzi, C. Feo, R. Mazza, G. Farina, A. Spadano, F. Pisani, L. Podda, G. Aitoro, V. Magarotto, M. Astolfi, F. Di Raimondo, G. Gaidano, M. Boccadoro (A.O.U. San Giovanni Battista, Turin, Italy)

FIRST ANALYSIS OF HOVON-65/GMMG-HD4 RANDOMIZED PHASE III TRIAL COMPARING BORTEZOMIB, ADRIAMYCINE, DEXAMETHASONE (PAD) VS VAD AS INDUCTION TREATMENT PRIOR TO HIGH DOSE MELPHALAN (HDM) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)
P. Sonneveld, B. van der Holt, I.G.H. Schmidt-Wolf, U. Bertsch, L. El Jarari, H. Salwender, S. Zweegman, E. Vellenga, J. Schubert, I.W. Blau, G.S.K. Jie, B. Beverloo, A. Jauch, D. Hose, R. Schaafsma, M.J. Kersten, M. Delforge, R.A. Raymakers, O. De Weerdt, R. Van der Griend, P.W. Weijermans, H. Martin, H. Van der Velde, H.M. Lokhorst, H. Goldschmidt (Erasmus MC, Rotterdam, The Netherlands)

SAFETY AND EFFICACY UPDATE OF PX-171-00, AN OPEN-LABEL PHASE II TRIAL OF CARFILZOMIB IN RELAPSED MULTIPLE MYELOMA
K. Stewart, D. Siegel, M. Wang, A. Jakubowiak, S. Jagannath, K. McDonagh, V. Kukreti, S. Lonial, M.H. Le, S. Cruickshank, R. Vij (Hackensack University Medical Center, Hackensack, USA)

LONG TERM FOLLOW UP OF A COMPARISON OF NONMYELOABLATIVE ALLOGRAFTING WITH AUTOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA
B. Bruno, R. Sorasio, F. Patriarca, N. Mordini, B. Allione, F. Carnevale-Schianca, L. Giaccone, M. Festuccia, M. Aglietta, A. Levis, A. Gallamini, R. Fanin, A. Palumbo, G. Ciccone, M. Boccadoro (Division of Hematology, Turin, Italy)

SUBCUTANEOUS OMACETAXINE MEPESUCCINATE IN IMATINIBRESISTANT CHRONIC MYELOID LEUKEMIA (CML) PATIENTS (PTS) WITH THE T315I MUTATION - DATA FROM AN ONGOING PHASE 2/3 TRIAL
J. Cortes, H.J. Khoury, F.E. Nicolini, S. Corm, T. Schenk, A. Hochhaus, D. Jones, H. Kantarjian, A.R. Craig, A.C. Benichou, E. Humphriss, M. Michallet (MD Anderson Cancer Center, Houston, USA)

MULTICENTER OPEN LABEL STUDY OF SUBCUTANEOUS (SC) OMACETAXINE MEPESUCCINATE IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS THAT ARE RESISTANT OR INTOLERANT TO TWO OR MORE TYROSINE KINASE INHIBITORS (TKIS)
M. Wetzler, P.M. Parikh, D. Raghunadharao, D. Jones, A. Leitner, A. Hochhaus, A.-C. Benichou, A.R. Craig, E. Humphriss, H. Kantarjian, J. Cortes (Roswell Park Cancer Institute, Buffalo, USA)

RANDOMIZED CLINICAL TRIAL FOR THE OPTIMIZATION OF IMATINIB THERAPY BY COMBINATION, DOSE ESCALATION AND TRANSPLANTATION. DESIGNED FIRST INTERIM ANALYSIS OF THE GERMAN CML STUDY IV
R. Hehlmann, S. Sau_ele, M. Lauseker, A. Leitner, N. Pletsch, C. Haferlach, B. Schlegelberger, M.C. Müller, T. Schenk, M. Pfirrmann, G. Ehninger, T. Fischer, J. Hasford, A. Hochhaus, D.K. Hossfeld, H.J. Kolb, S.W. Krause, C. Nerl, H. Pralle, A. Gratwohl, A. Tobler, H. Heimpel, L. Balleisen, H. Einsele, A.D. Ho, C. Falge, M. Hänel, M. Pfreundschuh, L. Kanz, H. Döhner, C. Köhne (Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany)

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN THE ERA OF TARGETED THERAPY: COMPARABLE SURVIVAL RATES FOLLOWING ALLOGENEIC HSCT AFTER IMATINIB AND IMATINIB THERAPY IN FIRST CHRONIC PHASE RESULTS OF THE GERMAN CML STUDY IV
S. Saussele, M. Lauseker, A. Gratwohl, D.W. Beelen, D. Bunjes, R. Schwerdtfeger, H.J. Kolb, A.D. Ho, C. Falge, E. Holler, G. Schlimok, A. Zander, R. Arnold, L. Kanz, R. Dengler, C. Haferlach, B. Schlegelberger, M. Pfirrmann, M.C. Müller, S. Schnittger, A. Leitner, N. Pletsch, A. Hochhaus, J. Hasford, R. Hehlmann, The Germa For (Universitätsmedizin Mannheim, Mannheim, Germany)

PHASE II MULTICENTRIC EXPLORATIVE STUDY OF INTERMITTENT IMATINIB (IM) TREATMENT (INTERIM) IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA (CML) WHO ACHIEVED A STABLE COMPLETE CYTOGENETIC RESPONSE (CCGR) WITH STANDARD IM THERAPY
D. Russo, G. Rosti, G. Martinelli, M. Malagola, S. Mirto, D. Turri, U. Vitolo, P. Pregno, M. Gobbi, I. Pierri, F. Di Raimondo, F. Stagno, R. Foà, G. Alimena, M. Breccia, G. Saglio, G. Rege Cambrin, P. De Fabritiis, E. Abruzzese, R. Fanin, M. Tiribelli, P. Galieni, C. Bigazzi, V. Liso, G. Specchia, A. Rambaldi, T. Intermesoli, F. Lauria, M. Bocchia, G. Quarta, M. Girasoli (Chair of Haematology, Brescia, Brescia, Italy)

IMMUNOCHEMOTHERAPY WITH RITUXIMAB IN ADULT CD20+ B-PRECURSOR ALL IMPROVES MOLECULAR CR RATE AND OUTCOME IN STANDARD RISK (SR) AS WELL AS IN HIGH RISK (HR) PATIENTS WITH SCT
D.H. Hoelzer, A.M. Huettmann, F.K. Kaul, S.I. Irmer, N.J. Jaeckel, M. Mohren, T. Lipp, K. Wendelin, F. del Valle, M. Schmid, E. Thiel, M. Brueggemann, M. Kneba, N. Goekbuget (Onkologikum Frankfurt am Museumufer, Frankfurt, Germany)

BLINATUMOMAB (ANTI-CD19 BITE_) FOR TARGETED THERAPY OF MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH B PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): UPDATE OF AN ONGOING PHASE II STUDY
M.S. Topp, N. Goekbuget, P. Kufer, G. Zugmaier, M. Klinger, E. Degenhard, S. Neumann, H.A. Horst, T. Raff, A. Viardot, M. Schmid, O. Ottmann, T. Burmeister, M. Schmidt, C. Reinhardt, H. Einsele, P.A. Baeuerle, D. Nagorsen, G. Riethmüller, D. Hoelzer, R.C. Bargou (University Hospital, Med. Department II, Wurzburg, Germany)

DASATINIB (SPRYCEL_) AND CHEMOTHERAPY FOR FIRST-LINE TREATMENT IN ELDERLY PATIENTS WITH DE NOVO PHILADELPHIA POSITIVE ALL (EWALL-PH-01): ANALYSIS OF RESPONSE ANDRESISTANCE
P. Rousselot, J.M. Cayuela, S. Hayette, C. Recher, T. Leguay, C. Salanoubat, F. Witz, M. Alexis, M. Janvier, M. Hunault-Berger, P. Agape, C. Berthou, E. Jourdan, J. Fernandes, L. Sutton, A. Banos, O. Reman, B. Lioure, N. Gökbuget, D. Hoelzer, A. Delannoy, R. Bassan, J. Ribera, S. Giebel, O. Ottmann, H. Dombret (Hôpital de Versailles, Le Chesnay, France)

IMATINIB AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) FOR PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL): INTERIM ANALYSIS OF A RANDOMIZED PHASE III STUDY
G. Ottmann, B. Wassmann, H. Pfeifer, M. Bornhäuser, W. Bethge, J. Dengler, M. Stadler, D.W. Beelen, N. Basara, R. Schwerdtfeger, K. Schäfer-Eckhart, L. Uharek, M. Stelljes, H. Serve, D. Hoelzer (University of Frankfurt, Frankfurt, Germany)

FLOW-CYTOMETRIC IMMUNOBEAD ASSAYS FOR THE DETECTION OF FUSION PROTEINS IN PRECURSOR B- ACUTE LYMPHOBLASTIC LEUKEMIA AND ACUTE MYELOID LEUKEMIA
E.H.A. Dekking, A.L. Noordijk, A. van der Linden, V.H.J. van der Velden, N. Boeckx, J.J.M. van Dongen (Erasmus Medical Center, Rotterdam, The Netherlands)

ACQUIRED MUTATIONS IN TET2 ARE COMMON IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
S.M.C. Langemeijer, R.P. Kuiper, M. Berends, R. Knops, M.G. Aslanyan, M. Massop, E. Stevens-Linders, P. van Hoogen, A. Geurts van Kessel, R.A.P. Raymakers, E.J. Kamping, G.E. Verhoef, E. Verburgh, A. Hagemeijer, P. Vandenberghe, T. de Witte, B.A. van der Reijden, J.H. Jansen (University Medical Center Nijmegen St Radboud, Nijmegen, The Netherlands)

PREVALENCE AND PROGNOSTIC IMPACT OF TET2 MUTATIONS IN MDS
F. Kosmider, V. Gelsi-Boyer, M. Cheok, S. Grabar, P. Guardiola, O. Beyne-Rauzy, B. Quesnel, E. Solary, N. Vey, M. Hunault-Berger, P. Fenaux, V. Mansat de Mas, F. Viguie, C. Lacombe, W. Vainchenker, C. Preudhomme, D. Birnbaum, F. Dreyfus, O.A. Bernard, M. Fontenay (Institut Cochin, APHP, Paris, France)

GAIN-OF-FUNCTION MUTATIONS OF C-CBL TUMOR SUPPRESSOR IN MDS AND MDS/MPD ASSOCIATED WITH 11Q UPD
M. Sanada, T. Suzuki, L.Y. Shih, M. Otsu, S. Yamazaki, M. Kato, H. Honda, M. Sakata-Yanagimoto, K. Kumano, H. Oda, J. Takita, N. Goto, N. Kawamata, E. Uehara, Y. Hayashi, H. Harada, M. Kurokawa, S. Chiba, H. Mori, K. Ozawa, M. Omine, H. Nakauchi, H.P. Koeffler, S. Ogawa (University of Tokyo, Tokyo, Japan)

IS ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION A REASONABLE THERAPEUTIC OPTION FOR ELDERLY (= 60 YEARS) PATIENTS WITH DE NOVO MYELODYSPLASTIC SYNDROMES ?
U. Platzbecker, R. Trenschel, K. Schaefer-Eckart, C. Theuser, G. Ehninger, M. Bornhäuser, D. Beelen (Universitätsklinikum “Carl Gustav Carus” Dresden, Dresden, Germany)

ANALYSIS OF THE MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS
R. Invernizzi, M.G. Della Porta, V. Rosti, A. Gallì, E. Travaglino, P. Santambrogio, C. Marseglia, V. Matti, L. Malcovati, G. Bergamaschi, M. Cazzola, S. Levi (University of Pavia and Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy)

INHIBITION OF LEF-1 EFFECTIVELY INDUCES APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA IN VITRO AND IN VIVO
R.K. Gandhirajan, I. Gehrke, G. Plickert, A. Schlösser, E.K. Schmitt, M. Hallek, K.A. Kreuzer (University Clinic Cologne, Cologne, Germany

TP53 MUTATION IN THE ABSENCE OF 17P DELETION DEFINES A GROUP OF PATIENTS WITH POOR OUTCOME IN CLL: ANALYSIS WITHIN THE CLL4 TRIAL (F VS. FC) OF THE GCLLSG
T. Zenz, B. Eichhorst, R. Busch, T. Denzel, S. Häbe, D. Winkler, A. Bühler, M Hallek, H. Döhner, S Stilgenbauer (University of Ulm, Ulm, Germany)

DIFFERENTIAL GENOME-WIDE METHYLATION PROFILES IN PROGNOSTIC SUBSETS OF CHRONIC LYMPHOCYTIC LEUKEMIA
M. Kanduri, N. Cahill, H. Göransson, C. Enström, A. Isaksson, R. Rosenquist (Uppsala University, Uppsala, Sweden)

SINGLE-AGENT OFATUMUMAB, A NOVEL CD20 MONOCLONAL ANTIBODY, RESULTS IN HIGH RESPONSE RATES IN PATIENTS WITH FLUDARABINE-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ALSO REFRACTORY TO ALEMTUZUMAB OR WITH BULKY LYMPHADENOPATHY
B. Wierda, A. Österborg, T. Kipps, J. Mayer, S. Stilgenbauer, C.D. Williams, A. Hellmann, T. Robak, R. Furman, P. Hillmen, M. Trneny, M.J.S. Dyer, S. Padmanabhan, M. Piotrowska, T. Kozak, G Chan, R. Davis, N. Losic, J. Wilms, C. Russell, W.G. Wierda, 406 Study Investigators (Karolinska University Hospital, Stockholm, Sweden)

PHASE I STUDY OF RO507275 (GA101) IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
G. Cartron, T. Lamy, F. Morschhauser, N. Milpied, C. Thieblemont, H. Tilly, J. Birkett, P. Pisa, G. Salles (CHU Montpellier, Montpellier, France)

AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) VS ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) AS FIRST TRANSPLANT PROCEDURE IN PATIENTS WITH WALDESTRÖM MACROGLOBULINEMIA. RESULTS OF A RETROSPECTIVE ANALYSIS OF THE LYMPHOMA WORKING PARTY OF THE EBMT
A. Sureda, C. Canals, C. Kyriakou, C. Gisselbrecht, M. Gramatzki, M. Kazmi, J.Y. Cahn, N. Milpied, K. Kolbe, W. Arcese, P. Corradini, D. Niederwieser, J.P. Jouet, K. Thomson, R.M. Hamladji, K. Indrak, N. Schmitz (Hospital de Sant Pau, Barcelona, Spain)

BORTEZOMIB INDUCTION BEFORE AUTOLOGOUS TRANSPLANTATION, FOLLOWED BY LENALIDOMIDE CONSOLIDATION-MAINTENANCE IN UNTREATED ELDERLY MULTIPLE MYELOMA PATIENTS
A. Palumbo, F. Gay, V. Montefusco, C. Crippa, F. Rossini, A.M. Liberati, F. Patriarca, M.T. Petrucci, M. Offidani, N. Giuliani, T. Guglielmelli, N. Pescosta, A. Larocca, P. Omedè, T. Caravita, A.M. Rauco, P. Corradini, G. Rossi, M. Boccadoro (A.O.U. San Giovanni Battista, Turin, Italy)

ALLOGENEIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN FIRST COMPLETE REMISSION: EXPERIENCE OF THE GMALL STUDIES
R. Arnold, D. Beelen, M. Bornhaeuser, D. Bunjes, J. Finke, N. Kroeger, M. Stadler, M. Stelljes, N. Goekbuget, D. Hoelzer (Charité University Medicine Berlin, Berlin, Germany)

AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE SCLEROSIS PATIENTS: A 10-YEAR EXPERIENCE OF THE RUSSIAN-AMERICAN COOPERATION
A. Novik, Y. Shevchenko, A. Kuznetsov, B. Afanasiev, I. Lisukov, O. Rykavicin, A. Myasnikov, T. Ionova, V. Melnichenko, D. Fedorenko, K. Kurbatova, R. Ivanov, N. Osipova, A. Kulagin, S. Shamansky, R. Kruglina, A. Kartashov, G. Gorodokin (Pirogov National Medical Surgical Center, Moscow, Russian Federation)

INTRA-BONE MARROW (IBM) TRANSPLANT OF CORD BLOOD CELLS IS ASSOCIATED WITH BETTER ENGRAFTMENT, FASTERPLATELET RECOVERY AND LESS SEVERE AGVHD AS COMPAREDWITH INTRAVENOUS ADMINISTRATION. AN EUROCORD MATCHED PAIRED ANALYSIS
F. Frassoni, M. Labopin, M. Podesta, F. Gualandi, F. Sanchez-Guijo, F. Fagioli, M. Rovira, A.M. Raiola, G.L. Ubezio, R. Varaldo, M. Berger, F. Nesi, E. Carreras, D. Caballero, I. Ionescu, M. Gobbi, G.M. Sambuceti, N. Sacchi, A. Bacigalupo, E. Gluckman, V. Rocha (Centro Cellule Staminali e Terapia Cellulare, Genova, Italy)

FINAL RESULTS OF THE HDR2 STUDY - A EUROPEAN MULTICENTER TRIAL IN PATIENTS WITH RELAPSED HODGKIN LYMPHOMA
M. Engert, H. Haverkamp, P. Borchmann, H. Mueller, V. Diehl, H. Döhner, B. Metzner, A. Franke, L. Smardova, D. Niederwieser, M. Wilhelm, M.-E. Goebeler, N. Schmitz, A. Sureda, J.W. Baars, J. Raemaekers, A. Josting (Internal Medicine I, Cologne, Germany)

EARLY CHEMOTHERAPY INTENSIFICATION WITH BEACOPP IN HIGH-RISK, INTERIM-PET POSITIVE ADVANCED-STAGE HODGKIN LYMPHOMA, IMPROVES THE OVERALL TREATMENT OUTCOME OF ABVD: A GITIL MULTICENTER CLINICAL STUDY
A. Gallamini, F. Fiore, R. Sorasio, A. Rambaldi, C. Patti, C. Stelitano, S. Viviani, F. Di Raimondo, T. Feldman, A. Biggi, A. Rossi, A. Mistretta, V. Bonfante, A. Chiarenza, M. Cantonetti, P. Gavarotti, C. Tarella (Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy)

ROBUST ANTITUMOR ACTIVITY OF THE ANTIBODY-DRUG CONJUGATE SGN-35 WHEN ADMINISTERED EVERY 3 WEEKS TO PATIENTS WITH RELAPSED OR REFRACTORY CD30 POSITIVE HEMATOLOGIC MALIGNANCIES IN A PHASE 1 STUDY
A. Younes, A. Forero-Torres, N.L. Bartlett, J.P. Leonard, D.A. Kennedy, E.L. Sievers (M.D. Anderson Cancer Center, Houston, USA)

PET-CT ADAPTED THERAPY AFTER 3 CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA. RESULTS IN 118 PATIENTS
S. Pavlovsky, A. Pavlovsky, I. Fernandez, L. Zoppegno, I. Cerutti, M.A. Pavlovsky, M.V. Prates, A. Basquiera, C. Corrado, G. Milone, M. Cabrejo, H. Fernandez Grecco, G. Avila, V. Flores Dutrus, C. Gumpel, V. Cabanne, S. Saba, F. Lastiri (GATLA Grupo Argentino de Tratamiento de Leucemia Aguda, Buenos Aires, Argentina)

PANOBINOSTAT HAS ACTIVITY IN TREATMENT-REFRACTORY HODGKIN LYMPHOMA
D.J. DeAngelo, A. Spencer, O.G. Ottmann, T. Fischer, T. Kindler, K.N. Bhalla, A. Liu, K. Parker, H. Rupani, N. Homji, E. Ashton, M. Jalaluddin, G. Laird, J.W. Scott, H.M. Prince (Dana-Farber Cancer Institute, Boston, USA

NIPA CHECKPOINT CONTROL IS ESSENTIAL FOR EFFICIENT ONCOGENIC TRANSFORMATION BY C-MYC
A.L. Illert, C. Fritz, H. Kawaguchi, S.W. Morris, C. Peschel, U. Keller, J. Duyster (Klinikum rechts der Isar der TU München, Munich, Germany)

ABERRANT INTRACELLULAR RETENTION OF MUTATED RECEPTOR TYROSINE KINASE FLT3 IN HUMAN LEUKEMIC CELLS AS A POTENTIAL MECHANISM SUPPORTING THE PATHOGENESIS OF ACUTE MYELOID LEUKEMIA
S.K. Koch, M. Ryser, A. Jacobi, M. Bornhäuser, G. Ehninger, C. Thiede, Study All on behalf of the SAL (University Hospital Carl Gustav Carus Dresden, Dresden, Germany)

CSF-1-INDUCED OSCILLATIONS IN PI3K/AKT ARE REQUIRED FOR CASPASE ACTIVATION IN MONOCYTES UNDERGOING DIFFERENTIATION INTO MACROPHAGES
A.J. Jacquel, N.M. Benikhlef, P.J. Paggetti, N.L. Lalaoui, G.L. Guery, E.K.D. Dufour, M.C. Ciudad, C.R. Racoeur, O.R. Micheau, L.D. Delva, N.D. Droin, E.S. Solary (INSERM UMR86, Dijon, France)

EVIDENCE FOR AN ANTI-CANCER BARRIER IN A MIXED LINEAGE LEUKEMIA MOUSE MODEL IN VIVO
S. Takacova, J. Bartek, P. Luzna, V. Divoky (Faculty of Medicine, Palacky University, Olomouc, Czech Republic)

A HISTONE H3 LYSINE 9 TRIMETHYLATION SIGNATURE PREDICTS SURVIVAL IN AML PATIENTS
C. Müller-Tidow, H.U. Klein, A. Hascher, F. Isken, N. Thoennissen, S. Agrawal, Y. Wang, A. Becker, C. Thiede, G. Ehninger, U. Zur Stadt, S. Koschmieder, M. McClelland, W.E. Berdel, M. Dugas, H. Serve (University of Münster, Münster, Germany)

THE PERIPHERAL CANNABINOID RECEPTOR REGULATES HUMAN AND MOUSE HEMATOPOIESIS, BONE MARROW RECOVERY, AND HEMATOPOIETIC STEM AND PROGENITOR CELL MOBILIZATION
M. Alberich Jorda, S. Jiang, R. Zagozdzon, K. Parmar, P. Mauch, Y. Fu, A. Makriyannis, A.M. Zvonok, D.G. Tenen, S. Avraham, J.E. Groopman, H.K. Avraham (Harvard Stem Cell Institute, Boston, USA)

THE NOVEL CDK-INHIBITOR P26-INCA1 CONTROLS THE RESPONSE OF HEMATOPOIETIC STEM CELLS TO AGING ANG TOXIC STRESS
N. Bäumer, L. Tickenbrock, S. Koschmieder, P. Tschanter, S. Diederichs, S. Agrawal, M. Stehling, G. Köhler, W.E. Berdel, H. Serve, C. Müller-Tidow (University of Münster, Münster, Germany)

STRUCTURE-FUNCTION ANALYSIS OF HUMAN HEMATOPOIETIC PBX INTERACTING PROTEIN (HPIP): A NOVEL HUMAN STEM CELL REGULATORY PROTEIN
P. Kaur, C. Stadler, H. Wolfgang, K.R. Humphries, C. Buske, M. Feuring-Buske (Helmholtz- Muenchen, Munich, Germany)

THE ROLE OF THE MADS TRANSCRIPTION FACTOR MEF2C IN REGULATING MLL-LEUKEMIC AND HEMATOPOIETIC STEM CELLS
C. Stocking, A. Schüler, M. Schwieger, S. Horn, R. Slany, R. Delwel, J. Valk, U. Müller (Heinrich-Pette-Institute, Hamburg, Germany)

STAT5 MEDIATES MASSIVE EXPANSION OF LEUKEMIA STEM CELLS
M. Heuser, L. Sly, C. Lai, B. Argiropoulos, F. Kuchenbauer, M. Leung, G. Lin, C. Brookes, S. Fung, G. Krystal, R.K. Humphries (Hannover Medical School, Hannover, Germany)

RISK FOR AML/MDS TRANSFORMATION IN PHILADELPHIA NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASMS - A POPULATION-BASED NESTED CASE-CONTROL STUDY IN SWEDEN
J. Björkholm, A.R. Derolf, C. Ekstrand, S.Y. Kristinsson, B. Andreasson, G. Birgegard, O. Linder, C. Malm, B. Markevarn, L. Nilsson, J. Samuelsson, F. Granath, O. Landgren (Karolinska University Hospital, Stockholm, Sweden)

TREATMENT OF PROGRESSION OF MYELOPROLIFERATIVE NEOPLASM (MPN) TO MDS/AML BY AZACYTIDINE (AZA): A REPORT ON 44 PATIENTS (PTS)
S. Thepot, R. Itzykson, E. Raffoux, C. Recher, B. Quesnel, F. Dreyfus, T. Cluzeau, Y. Chait, S. Harel, J. Delauney, D. Schlaifer, A. Thyss, C. Salanoubat,C. Dartigeas, A. Stamatoulas, A. Marfaing koka, C. Dumontet, B. Cassinat, C. Zerhouni, M. Roussel, J.J. Kiladjian, C. Gardin, P. Fenaux, L. Ades (Hopital Avicenne, Bobigny, France)

PHASE II STUDY OF CEP-70, AN ORALLY AVAILABLE JAK2 INHIBITOR, IN PATIENTS WITH PRIMARY MYELOFIBROSIS AND POST POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
F. P.S. Santos, H. Kantarjian, N. Jain, D. Thomas, G. Garcia-Manero, J. Cortes, S. Verstovsek (University of Texas - M.D. Anderson Cancer Center, Houston, USA)

TG10134, A JAK2-SELECTIVE INHIBITOR, IS WELL TOLERATED IN PATIENTS WITH MYELOFIBROSIS AND SHOWS SUBSTANTIAL THERAPEUTIC ACTIVITY ACCOMPANIED BY A REDUCTION IN JAK2V617F ALLELE BURDEN
D. Pardanani, J. Gotlib, C. Jamieson, J. Cortes, M. Talpaz, R. Stone, M. Silverman, J. Shorr, D.G. Gilliland, A. Tefferi (Mayo Clinic, Rochester, USA)

ANAHYDRET: A EUROPEAN MULTICENTER PROSPECTIVE PHASE 3-STUDY: NON-INFERIORITY OF ANAGRELIDE COMPARED TO HYDROXYUREA IN NEWLY WHO-DIAGNOSED ET PATIENTS
E. Petrides, M. Gotic, M. Penka, J. Holowiecki, J. Thiele, H.M. Kvasnicka, R. Kralovics, H. Gisslinger (Hematology Oncology Center, Munich, Germany)

ETV6/RUNX1 ABROGATES THE SPINDLE CHECKPOINT AND DIRECTLY TARGETS ITS KEY PLAYER MAD2L1
R. Panzer-Grümayer, G. Krapf, U. Kaindl, A. Kilbey, G. Fuka, A. Inthal, R. Joas, J.C. Neil, O.A. Haas (St. Anna Kinderkrebsforschung, CCRI, Vienna, Austria)

LEUKEMIA-INITIATING CELLS ARE FREQUENT IN VERY HIGH RISK CHILDHOOD PRECURSOR B ACUTE LYMPHOBLASTIC LEUKEMIA
M. Schmitz, P. Mirkowska, M. Stanulla, M. Schrappe, J.-P. Bourquin, B. Bornhauser (University Children's Hospital Zürich, Zürich, Switzerland)

THE CALM INTERACTOR CATS REPRESSES THE TRANSACTIVATION CAPACITY OF THE LEUKEMOGENIC FUSION PROTEIN CALM/AF10 AND INTERACTS WITH KEY PROTEINS OF THE APOPTOTIC PATHWAY
L. Fröhlich Archangelo, P.A. Greif, L. Fontanari Krause, S.T.O. Saad, S.K. Bohlander (Hematology and Hemotherapy Center, Campinas, Brazil)

IDENTIFICATION OF GENETIC MUTATIONS THAT COOPERATE WITH CONSTITUTIVELY ACTIVE FLT3 IN THE INDUCTION OF ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
A.N. Lehmann, B. Niebuhr, K. Schulz, M. Ziegler, J. Meyer, S. Horn, C. Stocking (Heinrich-Pette-Institute, Hamburg, Germany)

PHOSPHO-PROFILING IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) REVEALS CONSTITUTIVE AND CYTOKINE INDUCED SPECIFIC SIGNATURES
M. Queudeville, H. Kunze, S.M. Eckhoff, K.-M. Debatin, L.H. Meyer (University of Ulm, Ulm, Germany)

FACTOR V LEIDEN MUTATION INCREASES THE RISK FOR VENOUS THROMBOEMBOLISM IN PATIENTS WITH MALIGNANCY
I. Pabinger, D. Dunkler, R. Vormittag, C. Ay, C. Marosi, R. Simanek, C.C. Zielinski, C. Mannhalter (Medical University Vienna, Vienna, Austria)

A POOLED ANALYSIS OF FOUR PIVOTAL STUDIES OF RIVAROXABAN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER ORTHOPAEDIC SURGERY: EFFECT ON SYMPTOMATIC VENOUS THROMBOEMBOLISM AND DEATH, AND BLEEDING
S. Haase, G.G. Turpie, M.R. Lassen, A.K. Kakkar, B.I. Eriksson, F. Misselwitz, T.J. Bandel, M. Homering, T. Westermeier, M. Gent (McMaster University, Hamilton, Canada)

RESIDUAL VEIN THROMBOSIS FOR ASSESSING THE OPTIMAL DURATION OF LOW-MOLECULAR WEIGHT HEPARIN AFTER CANCERRELATED DEEP VEIN THROMBOSIS: THE CANCER DACUS STUDY
S. Siragusa, Cancer Dacus Investigators (University of Palermo, Palermo, Italy)

A PHASE III STUDY OF ENOXAPARIN VERSUS ASPIRIN VERSUS LOW-DOSE WARFARIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED UP-FRONT WITH THALIDOMIDE BASED-REGIMENS
A. Palumbo, M. Cavo, S. Bringhen, F. Patriarca, D. Rossi, M.T. Petrucci, N. Pescosta, L. De Rosa, A.M. Liberati, A. Ledda, M. Rizzo, A. Granata, N. Di Renzo, L. Podda, S. Storti, D. Derudas, D. Cangini, R. Rizzi, L. Pantani, A. Baraldi, S. Palmieri, F. Gay, M.C. Pallotti, F. Di Raimondo, M. Boccadoro (A.O.U. San Giovanni Battista, Turin, Italy)

SCREENING FOR OCCULT MALIGNANCY IN PATIENTS WITH IDIOPATHIC VENOUS THROMBOEMBOLISM -THE TROUSSEAU INVESTIGATORSF.
F. van Doormaal, J.M.M.B. Otten (Slotervaart ziekenhuis, Amsterdam, The Netherlands)

AT THE TIME OF DIAGNOSIS, PH+ CELLS FROM BOTH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA AND ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS ALREADY HARBOUR BCR-ABL KINASE DOMAIN MUTATIONS
S. Soverini, A. Poerio, A. Vitale, A. Gnani, S. Colarossi, F. Castagnetti, I. Iacobucci, A. Lonetti, F. Palandri, G. Rosti, M. Amabile, S. Paolini,C. Papayannidis, G. Gugliotta, M. Vignetti, F. Mandelli, M. Baccarani, R. Foà, G. Martinelli (Department of Hematology/Oncology “Seràgnoli”, University of Bologna, Bologna, Italy)

IDENTIFICATION OF NEW GENES SUSTAINING BCR-ABL ONCOGENIC SIGNALLING AND CML PROGRESSION THROUGH A GENETIC TOOL BASED ON HUMAN BCR-ABL TRANSGENIC DROSOPHILA MELANOGASTER (DM)
F. Messa, R. Bernardoni, M. Pradotto, F. Arruga, E. Bracco, S. Carturan, C. Maffè, E. Messa, C. Panuzzo, I. Iacobucci, T. Kalebic, G. Martinelli, M. Baccarani, G. Saglio, D. Cilloni (University of Turin, Orbassano, Italy)

FREQUENT INACTIVATING MUTATIONS OF TET2 AND CBL ARE ASSOCIATED WITH ACQUIRED UNIPARENTAL DISOMY IN ATYPICAL CHRONIC MYELOID LEUKEMIA
T. Ernst, A. Chase, C. Hidalgo-Curtis, K. Zoi, C. Zoi, A. Hochhaus, A. Reiter, W. Vainchenker, F. Grand, N.C.P. Cross (Wessex Regional Genetics Laboratory, Salisbury, United Kingdom)

PH-NEGATIVE HEMATOPOIESIS EMERGING AFTER SUCCESSFUL TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA DYSPLAYS SEVERE AND PERSISTENT TELOMERIC LOSS AND IMPAIRED FUNCTIONAL PERFORMANCES
C. Lobetti Bodoni, D. Ferrero, E. Genuardi, D. Sia, M. Genuardi, V. Giai, A. Rocci, L. Monitillo, D. Drandi, A. Risso, S. Ferrero, G. Isaia, M. Lunghi, R. Passera, G. Gaidano, M. Boccadoro, C. Carlo-Stella, M. Ladetto (University of Turin, Turin, Italy)

LONG-TERM MUTATION FOLLOW-UP OF PHILADELPHIACHROMOSOME
POSITIVE LEUKEMIA PATIENTS TREATED WITH SECOND-GENERATION TYROSINE KINASE INHIBITORS AFTERIMATINIB FAILURE SHOWS THAT NEWLY ACQUIRED BCR-ABL KINASE DOMAIN MUTATIONS LEADING TO RELAPSE MAINLY ARISE DURING THE FIRST YEAR
S. Soverini, A. Gnani, S. Colarossi, F. Castagnetti, E. Abruzzese, S. Paolini, S. Merante, E. Orlandi, S. De Matteis, A. Gozzini, I. Iacobucci, F. Palandri, G. Gugliotta, C. Papayannidis, A. Poerio, M. Amabile, C. Cilloni, G. Rosti, M. Baccarani, G. Martinelli (Department of Hematology/ Oncology “Seràgnoli”, University of Bologna, Bologna, Italy)

– 10:45
0531 IDENTIFICATION OF TET2 AS A GENE FREQUENTLY MUTATED IN MYELOID DISORDERS
F. Kosmider, F. Delhommeau, S. Dupont, V. DellaValle, C. James, S. Trannoy, N. Casadevall, F. Dreyfus, C. Lacombe, J. Soulier, F. Viguie, M. Fontenay, W. Vainchenker, O.A. Bernard (Institut Cochin, APHP, Paris, France)

LEUKEMIA FUSION PROTEINS ARE NOT SUFFICIENT TO INITATE THE ABERRANT METHYLATION PROFILE ASSOCIATED WITH FULL LEUKEMIC TRANSFORMATION
S. Alvarez, J. Suela, M. Wunderlich, J. Wei, X. Aguirre, I. Martín-Subero,A. Maiques, F. Acquadro, S. Rodriguez-Perales, M.J. Calasanz, R. Siebert,F. Prósper, J.C. Mulloy, J.C. Cigudosa (Spanish National Cancer Research Centre, Madrid, Spain)

REFINEMENT OF CYTOGENETIC CLASSIFICATION IN AML: DETERMINATION OF PROGNOSTIC SIGNIFICANCE OF RARE RECURRING CHROMOSOMAL ABNORMALITIES AMONGST 5635 YOUNGER ADULTS TREATED IN THE UK MRC TRIALS
J. Grimwade, R. Hills, A.V. Moorman, H. Walker, S. Chatters, A.H. Goldstone, K. Wheatley, C.J. Harrison, A.K. Burnett (King's College London School of Medicine, London, United Kingdom)

CEBPA GENE MUTATIONS AFFECTING THE TAD AND BZIP REGION SHOW DIFFERERENCES IN THEIR ASSOCIATION WITH CLINICAL PARAMETERS AND PROGNOSIS: AN ANALYSIS IN 1779 ADULT PATIENTS WITH AML
F. Taube, T. Illmer, M. Schaich, F. Kroschinsky, U. Oelschlägel, B. Mohr, U. Platzbecker, G. Ehninger, C. Thiede, On behalf of the SAL (University Hospital TU Dresden, Dresden, Germany)CEBPA GENE MUTATIONS AFFECTING THE TAD AND BZIP REGION SHOW DIFFERERENCES IN THEIR ASSOCIATION WITH CLINICAL PARAMETERS AND PROGNOSIS: AN ANALYSIS IN 1779 ADULT PATIENTS WITH AML F. Taube, T. Illmer, M. Schaich, F. Kroschinsky, U. Oelschlägel, B. Mohr, U. Platzbecker, G. Ehninger, C. Thiede, On behalf of the SAL (University Hospital TU Dresden, Dresden, Germany)

A POLYMORPHIC CONSTITUTIONAL TFG-GPR128 FUSION IN HEALTHY INDIVIDUALS IDENTIFIED BY TARGETED ARRAY CGH
J. Chase, A. Fiebig, T. Ernst, F. Grand, A. Reiter, P. Erben, S. Schreiber, N. Cross (Wessex Regional Genetics Laboratory, Salisbury, United Kingdom)

FACTORS DETERMINING SURVIVAL AFTER UNRELATED DONOR ALLOGENEIC STEM CELL TRANSPLANTATION IN PRIMARY REFRACTORY ACUTE MYELOID LEUKAEMIA
C. Craddock, M. Labopin, C. Schmid, V. Rocha (Queen Elizabeth Hospital, Birmingham, United Kingdom)

A RANDOMIZED CONTROLLED CLINICAL STUDY : COINFUSIONG OF MESENCHYMAL STEM CELLS IN HAPLOIDENTICALHEMATOPOIETIC STEM-CELL TRANSPLANTATION CAN FACILITATE PLATELET RECOVERY BUT FAIL TO PREVENT GVHD
K.Y. Liu, C.H. Zhao, Y.H. Chen, L.P. Xu, H. Chen, D.H. Liu, X.H. Zhang, W. Han, Y. Wang, T. Zhao, J.Z. Wang, J. Wang, Q. Han, Y. Zeng, X.J. Huang (Institute of Hematology, People's Hospital, Peking University, Beijing, Cocos Islands)

A MULTICENTRIC COMPARATIVE ANALYSIS OF OUTCOMES OF HLA IDENTICAL RELATED CORD BLOOD AND BONE MARROW TRANSPLANTATION IN PATIENTS WITH BETA-THALASSEMIA OR SICKLE CELL DISEASE
N. Kabbara, F. Locatelli, V. Rocha, S. Grafakos, A. Ghavamzadeh, I. Roberts,C.K. Li, F. Bernaudin, C. Vermylen, J.H. Dalle, J. Stein, R. Wynn, P Lutz, C. Catherine, F. Pinto, E. Angelucci, G. Socie, E. Gluckman, M. Walters (Hopital Saint Louis, Paris, France)

HIGH THROUGHPUT IDENTIFICATION OF MINOR HISTOCOMPATIBILITY ANTIGENS BY WHOLE GENOME ASSOCIATION SCANNING
C.A.M. van Bergen, E.D. van der Meijden, S.A.P. van Luxemburg, E.G.A. Lurvink, C.E. Rutten, J.J. Houwing, M.L. Sampietro, C.J.M. Halkes, R. Willemze, J.H.F. Falkenburg, M. Griffioen (Leiden University Medical Center, Leiden, The Netherlands)

EXTRACORPOREAL PHOTOCHEMOTHERAPY FOR ACUTE AND CHRONIC GVHD, A REPORT OF 102 PATIENTS TREATED IN A SINGLE INSTITUTION
E.J. Dann, A. Badian, T. Stravets, E. Kertsman, S. Phenklbaum, T. Zuckerman, N. Haddad, R. Elhasid, L. Bonstein, J.M. Rowe (Rambam Medical Center, Haifa, Israel)